(¿Â¶óÀÎ) Á¦262ȸ ´ëÇÑ ¼Ò¾Æ¾Ë·¹¸£±â È£Èí±âÇÐȸ ¿ù·Ê ÇмúÁý´ãȸ : 2022-03-08±³À°ÀÏÀÚ : 2022-03-08
±³À°Àå¼Ò : ZoomÀ» ÀÌ¿ëÇÑ È»ó±³À°
±³À°ÁÖÁ¦ :
(¿Â¶óÀÎ) Á¦262ȸ ´ëÇÑ ¼Ò¾Æ¾Ë·¹¸£±â È£Èí±âÇÐȸ ¿ù·Ê ÇмúÁý´ãȸÁÖÃÖ±â°ü : ´ëÇѼҾƾ˷¹¸£±âÈ£Èí±âÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : Áß¾ÓÁöȸ
´ã´çÀÚ : ½É¼öÁÖ
¿¬¶ôó : 02-3276-2031
À̸ÞÀÏ :
kapard@kapard.or.kr ±³À°Á¾·ù : ¼Ò¾Æû¼Ò³â°ú
Âü¼®¿¹»óÀοø : 100¸í
Èñ¸ÁÆòÁ¡ : 2Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 2 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 10,000¿ø
ºñ°í Á¤È¸¿ø/Àü°øÀÇ ¹«·á, ºñȸ¿ø 10,000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 03-08 ¿Â¶óÀÎ 18:30~18:45 ¾ÆÅäÇÇÇǺο°¿¡¼ JAK1 InhibitorÀÇ »ç¿ë:1. Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis -The JADE TEEN Randomized Clinical Trial. JAMA Dermatol. 2021;157(10):1165-1173. ÃÖ¾öÁö(¼¿ï¾Æ»êº´¿ø ¼Ò¾Æû¼Ò³â°ú)
±³À°½Ã°£ 03-08 ¿Â¶óÀÎ 18:45~19:00 ¾ÆÅäÇÇÇǺο°¿¡¼ JAK1 InhibitorÀÇ »ç¿ë:2. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet 2021; 397: 2151–68 ÀÌ°æÈÆ(¼¿ï´ëÇб³º´¿ø ¾Æû¼Ò³â°ú)
±³À°½Ã°£ 03-08 ¿Â¶óÀÎ 19:00~19:30 Áõ·Ê: È£Èí°ï¶õÀ» ÁÖ¼Ò·Î ³»¿øÇÑ 12°³¿ù ³²¾Æ ½Å»óÈñ ±èÁöÇö ¾È°¸ð(»ï¼º¼¿ïº´¿ø û¼Ò³â°ú)
±³À°½Ã°£ 03-08 ¿Â¶óÀÎ 19:30~20:30 Ư°: ¿¬±¸¼º°ú ¹ßÇ¥¸¦ À§ÇÑ ±×·¡ÇÈÀÇ Á¦ÀÛ ·ùÁؼ±(±¹¸³¾Ï¼¾ÅÍ À̺ñÀÎÈÄ°ú)